New study aims to uncover hidden TB drug resistance
NCT ID NCT07169149
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will test 250 people with tuberculosis (TB) to see how common drug resistance is. Using special rapid tests called GeneXpert, researchers will look for resistance to key TB drugs like Rifampicin. They also want to find out if things like diabetes or drug addiction make resistance more likely. The goal is to help doctors pick the right treatment faster.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors choose the most effective TB drugs for each patient, reducing treatment failure.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly benefit participants and may not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRAPULMONARY TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sohag University
Sohag, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new patient cohort unlock the secrets of TB treatment success?
- Shorter TB treatment: a 4-Month regimen put to the test
- Lung damage after TB: a new study tests whether rehabilitation can restore breathing and quality of life
- Can a more powerful antibiotic clear TB faster? a trial puts rifapentine to the test.
- Could a simple screening strategy uncover hidden TB in COPD patients?
- Talking it out: could counseling be the key to beating TB?